Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Heining

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Pageof 2